Survival rates by race found similar with Abecma in myeloma study
Safety and response rates with Abecma (idecabtagene vicleucel) were…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Elrexfio for RRMM recommended in EU for conditional approval
A committee of the European Medicines Agency (EMA) has…
Effect of diabetes on survival in myeloma may differ by race: Study
While diabetes is more frequent among Black people than…
Phase 3 trial of Venclexta for hard-to-treat myeloma misses main goal
People with hard-to-treat multiple myeloma given a regimen…
Vaccine may help boost response to stem cell transplant: Phase 1 trial
A cell-based vaccine designed to promote immune responses against…
Phase 1b trial enrolling to test continuous low-dose lenalidomide
The Gabrail Cancer Center (GCC) in Canton, Ohio is…
